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SC68896, a novel small molecule proteasome inhibitor, exerts
antiglioma activity in vitro and in vivo
Abstract
PURPOSE: Glioblastomas are among the most lethal neoplasms, with a median survival of <1 year.
Modulation of the proteasome function has emerged as a novel approach to cancer pharmacotherapy.
Here, we characterized the antitumor properties of SC68896, a novel small molecule proteasome
inhibitor. EXPERIMENTAL DESIGN: Different tumor cell lines were tested by crystal violet staining
for sensitivity to SC68896, given alone or in combination with death ligands. The molecular
mechanisms mediating SC68896-induced cell death and changes in cell cycle progression were assessed
by immunoblot and flow cytometry. An orthotopic human glioma xenograft model in nude mice was
used to examine the in vivo activity of SC68896. RESULTS: SC68896 inhibits the proliferation of cell
lines of different types of cancer, including malignant glioma. Exposure of LNT-229 glioma cells to
SC68896 results in a concentration- and time-dependent inhibition of the proteasome, with a consequent
accumulation of p21 and p27 proteins, cell cycle arrest, caspase cleavage, and induction of apoptosis.
Using RNA interference, we show that the effect of SC68896 on glioma cells is facilitated by wild-type
p53. SC68896 sensitizes glioma cells to tumor necrosis factor-related apoptosis-inducing ligand and
CD95 ligand and up-regulates the cell surface expression of the tumor necrosis factor-related
apoptosis-inducing ligand receptor cell death receptors 4 and 5, which may contribute to this
sensitization. Intracerebral glioma-bearing nude mice treated either i.p. or intratumorally with SC68896
experience prolonged survival. CONCLUSIONS: SC68896 is the first proteasome inhibitor that exerts
antiglioma activity in vivo. It may represent a novel prototype agent for the treatment of malignant
gliomas and warrants clinical evaluation.
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TRANSLATIONAL RELEVANCE 
 
Despite recent advances in the treatment of malignant gliomas, these tumors remain a 
dominant challenge in the field of neurological oncology. Because of the poor prognosis of 
the affected patients, there is an urgent need to develop novel therapeutic strategies. Inhibition 
of the proteasome has attracted much attention as a promising approach for cancer therapy. 
However, bortezomib, the only drug that has been clinically approved for other tumor entities, 
failed to inhibit the growth of experimental gliomas in vivo. Here, we characterize the activity 
of SC68896, a novel proteasome inhibitor, against malignant gliomas. SC68896 induced 
apoptosis in glioma cells and sensitized them to death ligands. Most importantly, the survival 
of glioma-bearing mice was increased after intraperitoneal or intratumoral administration of 
SC68896. Based on these findings, our study provides a strong basis for a clinical evaluation 
of SC68896 as a novel therapeutic agent for glioma patients. 
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ABSTRACT 
 
Purpose: Glioblastomas are among the most lethal neoplasms with a median survival less 
than one year. Modulation of the proteasome function has emerged as a novel approach to 
cancer pharmacotherapy. Here we characterized the antitumor properties of SC68896, a novel 
small molecule proteasome inhibitor.  
Experimental Design: Different tumor cell lines were tested by crystal violet staining for 
sensitivity to SC68896, given alone or in combination with death ligands. The molecular 
mechanisms mediating SC68896-induced cell death and changes in cell cycle progression 
were assessed by immunoblot and flow cytometry. An orthotopic human glioma xenograft 
model in nude mice was used to examine the in vivo activity of SC68896. 
Results: SC68896 inhibits the proliferation of cell lines of different types of cancer, including 
malignant glioma. Exposure of LNT-229 glioma cells to SC68896 results in a concentration- 
and time-dependent inhibition of the proteasome with a consequent accumulation of p21 and 
p27 proteins, cell cycle arrest, caspase cleavage and induction of apoptosis. Using RNA 
interference, we demonstrate that the effect of SC68896 on glioma cells is facilitated by wild-
type p53. SC68896 sensitizes glioma cells to TRAIL and CD95 ligand and up-regulates the 
cell surface expression of the TRAIL receptors DR4 and DR5 which may contribute to this 
sensitization. Intracerebral glioma-bearing nude mice treated either intraperitoneally or 
intratumorally with SC68896 experience prolonged survival.  
Conclusions: SC68896 is the first proteasome inhibitor that exerts anti-glioma activity in 
vivo. It may represent a novel prototype agent for the treatment of malignant gliomas and 
warrants clinical evaluation. 
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INTRODUCTION 
 
Gliomas are intrinsic tumors of the brain that are characterized by resistance to apoptotic 
stimuli, local immunosuppression and diffuse infiltration of the surrounding healthy tissue. 
The currently available treatment options, including surgery, radio- and chemotherapy, aim at 
stopping the local destructive tumor growth. Despite all efforts, the current standard treatment 
of care prolongs the median survival of glioblastoma patients only to 12-15 months in 
selected patient populations (1). Due to the limited activity of the conventional 
chemotherapeutic agents, new therapeutic approaches are urgently needed to improve the 
prognosis of the affected patients. One of the potential new targets is the proteasome which is 
a protease complex responsible for the degradation of damaged or misfolded cellular proteins. 
It also removes proteins from the cell that influence cell cycle and growth (2). The 26S 
proteasome consists of two 19S subunits and the 20S proteasome core and has trypsin, 
chymotrypsin and caspase-like protease activities. The complex balance between synthesis 
and degradation of proteins is regulated by their ubiquitination status. Cells use long 
polyubiquitin chains to target proteins which are processed by the 26S proteasome, the site for 
ATP-dependent degradation of ubiquitin-tagged proteins. The ubiquitin-proteasome protein 
degradation pathway has thereby a central role within the regulation of cellular proliferation, 
differentiation and apoptosis (3). Targeting the proteasome with specific inhibitors represents 
a novel and logical approach to induce cell death. The clinical relevance of this pathway has 
been exemplified by the proteasome inhibitor bortezomib that shows beneficial effects in 
patients suffering from multiple myeloma and Non-Hodgkin’s lymphoma (4, 5). Bortezomib 
has also been shown to inhibit the growth of malignant glioma cells in vitro, however, it was 
not effective in the treatment of experimental glioma xenografts in vivo (6). Additionally, 
there is also a lack of clinical data proving its activity in patients with malignant gliomas. 
Therefore, the aim of the present study was to characterize the effects of a novel proteasome 
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inhibitor, SC68896, on glioma cell survival in vitro and in vivo. Since gliomas are 
paradigmatic for resistance to therapy, a multitude of mechanisms has been explored to 
induce apoptosis in these cells. Theoretically, the induction of apoptosis by systemic or local 
application of death ligands such as TNF-related apoptosis-inducing ligand (TRAIL, 
alternative name Apo2 ligand) and CD95 ligand (CD95L) offers the possibility to target 
tumor cells. TRAIL mediates proapoptotic effects in the treatment of experimental gliomas 
through cell death receptors (DR) 4 and 5 which are expressed on the surface of these cells 
(7). By contrast, binding of TRAIL to the decoy receptors (DcR) 1 and 2 fails to induce 
apoptosis. As a result of these anti-apoptotic mechanisms, glioma cells exhibit a significant 
resistance towards TRAIL. Accordingly, we explored a direct effect of SC68896 on glioma 
cell proliferation in vitro and its effects on cell cycle progression. Additionally, we assessed a 
possible sensitization of glioma cells to TRAIL- and CD95L-induced apoptosis by this novel 
compound. The in vivo activity was evaluated in an orthotopic glioma nude mouse model by 
intratumoral or systemic intraperitoneal application of SC68896.  
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MATERIALS AND METHODS 
 
Materials and cell lines 
SC68896 belongs to a new family of proteasome inhibitors. It was discovered by 4SC AG, a 
company that develops novel drug candidates based on the results of high-throughput 
screenings. The chemical synthesis of SC68896 has been described before (8). A stock 
solution was prepared in dimethylsulfoxide (DMSO) and stored at -20°C. TRAIL was 
purchased from Peprotech (Rocky Hill, NJ, USA). CD95L-containing supernatant was 
harvested from CD95L-transfected N2A neuroblastoma cells (9). Propidium iodide (PI) and 
all other reagents, unless indicated otherwise, were purchased from Sigma (St. Louis, MO, 
USA). Antibodies against human p21, p27 and poly(ADP-ribose) polymerase (PARP) were 
from BD Bioscience (Heidelberg, Germany), antibody to p53 was purchased from Santa Cruz 
(Santa Cruz, CA, USA). Antibody against cleaved caspase 3 was from Cell Signalling 
(Danvers, MA, USA). Antibody against caspase 3 was obtained from Merck (Darmstadt, 
Germany) and against caspase 8 from Alexis (San Diego, CA, USA). GAPDH antibody was 
purchased from Chemicon (Temecula, CA, USA). DAOY medulloblastoma, the MCF-7 
breast adenocarcinoma and K-562 chronic myelogenous leukemia cell lines were obtained 
from the American Type Culture Collection (ATCC, Rockville, MD, USA). HCT-116 
colorectal carcinoma cells were a kind gift of B. Vogelstein (Baltimore, MD, USA). All other 
glioma cell lines were kindly provided by Dr. N. de Tribolet (Lausanne, Switzerland). K-562 
cells were maintained in RPMI 1640 supplemented with 1 mM sodium pyruvate (Gibco Life 
Technologies, Paisley, UK), penicillin (100 IU/ml)/streptomycin (100 µg/ml) (Gibco) and 
10% fetal calf serum (FCS) (Biochrom KG, Berlin, Germany). All other cell lines were 
cultured in Dulbecco’s modified Eagle’s medium (DMEM) containing 10% FCS, 2 mM 
glutamine and penicillin (100 IU/ml)/streptomycin (100 g/ml). Primary glioblastoma cells 
were established from freshly resected tumors, cultured in monolayers and used between 
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passages 4 and 9 (10). The generation of stable LNT-229-p53si cells by RNA interference has 
been described (11). 
 
Viability assays 
The cells were seeded at 5 x 103 cells per well in 96-well plates, allowed to attach for 24 h, 
and subsequently exposed to SC68896 as indicated. Cell density was assessed by crystal 
violet staining for adherent cells. 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium 
bromide (MTT) assay was used to determine the viability of non-adherent cells (12). 
 
Immunoblot analysis  
The cells were treated with SC68896 or solvent control containing DSMO and lysed. Cellular 
soluble proteins (20 µg/lane) were harvested and separated on 10% acrylamide gels (Biorad, 
Munich, Germany). After transfer to nitrocellulose (Biorad), the blots were blocked in PBS 
containing 5% skim milk and 0.05% Tween 20 and incubated overnight at 4°C with 
antibodies to p21, p27, p53, PARP, -actin or GAPDH. Visualization of protein bands was 
accomplished using HRP-coupled secondary antibodies (Santa Cruz) and ECL (Amersham, 
Braunschweig, Germany).  
 
Flow cytometry 
For cell cycle analysis, glioma cells were treated with SC68896 as indicated, harvested, fixed 
and permeabilized over night in ice-cold 70% ethanol (Merck). The cells were washed twice 
with PBS. RNA was digested with RNase A (Gibco). The DNA was stained with propidium 
iodide PI (50 g/ml). Fluorescence was recorded in a CyAn ADP S2536 analyzer  (Dako 
Cytomation, Carpinteria, CA). Cells that appeared left of the G0/G1 peak were considered to 
have a DNA content below 2n, indicative of cell death. Aggregated cells were gated out. For 
analysis of cell death, LNT-229 cells were grown in six-well plates, incubated with SC68896 
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at different concentrations for 24 h, washed in phosphate-buffered saline (PBS) and 
resuspended in 10 mM 4-(2-hydroxyethyl)-1-piperazineethanesulfonic acid/NaOH, pH 7.4, 
140 mM NaCl, and 2.5 mM CaCl2. AnxV-fluorescein isothiocyanate (1:100) and PI (50 
µg/ml) were added, and fluorescence in a total of 10,000 events per condition was recorded in 
a CyAn flow cytometer. AnxV-fluorescein isothiocyanate- or PI-positive cells were counted 
as dead cells (either apoptotic or necrotic), and the remaining cells were designated the 
surviving cell fraction. 
To analyze the cell surface expression of TRAIL receptors and CD95, the cells were 
incubated with or without SC68896 as indicated, harvested using Accutase (PAA, Vienna, 
Austria) and washed with PBS. The following steps were carried out at 4°C in flow cytometry 
buffer (PBS, 1% bovine serum albumin (BSA), 1% FCS). The cells were incubated for 1 h 
with 10 µg/ml mouse isotype control antibody or mouse anti-human DR4 clone 69036, DR5 
clone 71908, DcR1 clone 90906, DcR2 clone 104918 (all R&D Systems, Minneapolis, MN, 
USA) or mouse anti-human CD95 clone DX2 (Santa Cruz). After 2 further washes, 4 g/ml 
biotinylated rabbit anti-mouse F(ab’)2 (Dako Cytomation) were added for 20 min. Following 
2 more washes, the cells were stained for 20 min in 2 g/ml streptavidin-allophycocyanin 
(BD Bioscience). Unbound staining reagent was removed by washing, PI (50 µg/ml) was 
added and receptor expression was analyzed by flow cytometry. PI-positive, i.e. dead cells 
were gated out. The median fluorescence intensities of the samples achieved with specific 
antibody were divided by those achieved with isotype control antibody to obtain specific 
fluorescence indexes (SFI).  
 
Proteasome activity assay 
The activity of the three enzymatic sites of the proteasome was separately determined using 
commercially available kits (Proteasome-Glo, Promega, Madison, WI, USA). These are 
luminescent assays based on the measurement of the chymotrypsin-like, trypsin-like and 
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caspase-like activity associated with the proteasome complex in the investigated cells. Briefly, 
104 cells per well were seeded in 96-well plates, allowed to adhere for 24 h, treated with 
SC68896 as indicated and assessed for the enzymatic activities of the proteasome according to 
the manufacturer’s protocol. To assess the activity of the proteasome in whole blood, 10 l of 
blood were taken from the tail vein of mice treated with SC68896 or vehicle and assessed by 
Proteasome-Glo. 
 
Mice and animal experiments 
Athymic CD1 nude mice were purchased from Charles River Laboratories (Sulzfeld, 
Germany). Mice of 6–12 weeks of age were used in all experiments. The experiments were 
performed according to NIH guidelines, Guide for the Care and Use of Laboratory Animals. 
Before all intracranial procedures mice were anesthetized by an intraperitoneal injection of 
7% chloral hydrate. For intracranial implantation the mice were placed in a stereotactic 
fixation device (Stoelting, Wood Dale, IL, USA) and a burr hole was drilled in the skull 2 mm 
lateral to the bregma. The needle of a Hamilton syringe (Hamilton, Darmstadt, Germany) was 
introduced to a depth of 3 mm. LNT-229 glioma cells (7.5 x 104) in a volume of 2 µl PBS 
were injected into the right striatum. For the local application of SC68896, 80 g of SC68896 
or 2 l of DMSO were injected intratumorally 3 times in 8 mice per group. For the i.p. 
administration, a SC68896 solution, containing 5% of DMSO, 10% of cremophor and NaCl 
0.9% was produced daily and administered 5 days per week. To assess the inhibition of the 
proteasome in vivo, 10 µl of blood were taken from 6 mice of each group after 15 days of 
therapy and the activity of the proteasome was assessed with the Proteasome-Glo kit. Both 
groups of 14 mice were observed daily and the animals were sacrificed at the onset of 
neurological symptoms. 
For the assessment of tumor growth and histology, 2 animals per group were killed 2 days 
after the second intratumoral injection and cryostat brain sections (8 µm) were stained with 
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hematoxylin and eosin (HE). For immunohistochemical stainings, the following antibodies 
were used: rabbit anti-von Willebrand factor (DAKO, Glostrup, Denmark), mouse anti-p21 
(Calbiochem, San Diego, CA, USA) and mouse anti-Ki-67 (Zymed, San Francisco, CA, 
USA). Subsequently, the slices were stained with secondary antibody and developed with 
Dolichos biflorus agglutinin (DAB; Vectastain, Vector Laboratories, Burlingame, CA, USA). 
Tumor-containing sections of each brain were used for terminal deoxynucleotidyl transferase-
mediated nick-end labeling (TUNEL) staining (Roche, Basel, Switzerland). 
 
Data analysis  
Data are representative of experiments performed three times with similar results. Viability 
and proliferation studies were performed using triplicate wells. Where indicated, analysis of 
significance was performed using the Mann-Whitney-Wilcoxon or the two-tailed Student’s t-
test (*p<0.05; **p<0.01). Synergy of SC68896 and death ligands was evaluated using the 
fractional product method. Here, “predicted values” correspond to an additive action of 2 
compounds that can be compared to the observed effect (13). Additionally, the combination 
index (CI) for each of the combinations was evaluated using Calcusyn software (Biosoft, 
Cambridge, UK). The program uses the multiple drug effect equation of Chou-Talalay. When 
testing a drug combination, the software calculates for each fractional effect point a specific 
parameter, the CI, which indicates the interactive effect of the drugs. Synergy levels were 
classified according to the Calcusyn manual: CI < 0.9 indicates synergy; CI = 0.9 to 1.1 is 
additive; and CI > 1.1 means antagonism.  
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RESULTS 
 
SC68896 inhibits the proliferation of different tumor cell lines  
To assess its effect on tumor cell proliferation, we administered different concentrations of 
SC68896 to tumor cell lines from different origin. Exposure to SC68896 led to a time- and 
concentration-dependent inhibition of cell density, showing highest activity against HCT-116 
colon carcinoma cells. When compared to cells that were grown in medium alone, the 
proliferation was massively diminished after exposure to SC68896 for 72 h (Fig. 1A). The 
same observation was made when SC68896 was added to glioma cell cultures in different 
concentrations with highest efficacy against LNT-229 and U373MG cells (Fig. 1B). Exposure 
to SC68898 of primary glioma cells showed modest effects after 24 h, but a considerable 
decrease of cell density after 48 and 72 h (Fig. 1C). To assess the effect of short-time 
exposure of SC68896 on glioma cells, we exposed LNT-229 glioma cells for 1, 3 or 6 h to 
SC68896 and evaluated the cell density after 24 h (Fig. 1D, left panel) or 72 h (right panel). 
Compared to a continuous exposure for 24 or 72 h, we noticed smaller but still considerable 
effects on the proliferation of these cells. 
 
SC68896 acts as an inhibitor of the proteasome in glioma cells and induces cell cycle 
arrest 
Since SC68896 was designed as an inhibitor of the cellular proteasome (8), we used 
commercially available kits to confirm its effect on the 3 enzymatic activities of the 
proteasome of glioma cells. Intriguingly, the chymotryptic site was reduced to less than 20% 
after exposure to 1 or 10 M SC68896 for 3 h. Since no effect on cell density was observed at 
this point, this is not the result of a reduced number of tumor cells investigated. We then 
aimed at assessing the potential recovery of proteasomal function and measured the activity of 
the enzymatic sites at 3, 9 or 21 h after removal of the compound. The chymotryptic site 
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remained completely inhibited after exposure to 10 M SC68896. In contrast, we noticed a 
slow recovery in cells that had been treated with 1 M or less of the compound. When 
SC68896 was continously administered for 24 h, the proteasomal activity remained inhibited 
at concentrations of 1 M or more. The trypsin-like and caspase-like sites of the proteasome 
were only slightly affected by SC68896, indicating a high specificity for the chymotryptic site 
(Fig. 2A). 
To allow for a better understanding of the mechanisms underlying the inhibition of glioma 
cell proliferation, we next investigated whether exposure to SC68896 influences cell cycle 
and cell cycle-related proteins. Using immunoblot, we found a slight increase of p27 levels 
and a massive induction of p21 expression in LNT-229 cells after treatment with SC68896 for 
24 h. Accumulation was p53-independent because it was maintained when the wild-type p53 
gene was silenced by RNA interference (Fig. 2B). In order to investigate the mechanism of 
growth inhibition in more detail we analyzed the effects of SC68896 on cell cycle distribution 
by flow cytometry. The antiproliferative effect of SC68896 was accompanied by a massive 
G2/M arrest and an increase in cells with sub-G1 DNA content (Fig 2C).  
 
Glioma cell sensitivity towards SC68896 is modulated by p53 
Since p53 plays an important role in cell cycle control and in the induction of apoptosis in 
response to various cellular stress signals, we asked whether SC68896 exerts p53-dependent 
antiproliferative or cytotoxic effects. To obtain a cell-based experimental system that allows 
distinguishing between p53-dependent and -independent effects, we used LNT-229 cells with 
a siRNA-mediated stable p53 knock-down. Compared to cells transfected with a scrambled 
control plasmid, hardly any p53 expression was detectable in LNT-229-p53si cells (Fig. 2D, 
inset). SC68896 inhibited the proliferation of the LNT-229 sublines partially in a p53-
dependent manner since the p53-deleted cells were much more resistant (Fig. 2D, upper 
pannel). Irrespective of p53 status, administration of SC68896 led to a similar inhibition of 
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the chymotryptic activity of the proteasome (lower panel), indicating that p53 protects the 
cells down-stream of proteasome inhibition.  
 
Administration of SC68896 induces apoptosis and activation of caspases in glioma cells 
Administration of SC68896 for 24 h induced apoptosis in LNT-229 glioma cells as assessed 
by AnxV/PI staining. This effect was concentration-dependent with the highest percentage of 
apoptotic cells at 25 M (Fig. 3A). These findings are in accordance with the effects of 
SC68896 on glioma cell proliferation after exposure for 24 h (combined results in Fig. 3A, 
lower panel). We next asked whether activation of caspases occurs after application of 
SC68896. To this end, whole cell lysates were generated after treatment of LNT-229 cells for 
24 h with different concentrations of SC68896. Immunoblot revealed the proteolytic 
processing of caspases 3 and 8 (Fig. 3B) and cleavage of PARP (Fig. 3C). 
 
SC68896 sensitizes human malignant glioma cell lines to TRAIL- and CD95L-induced 
cell death 
Resistance of glioma cells to apoptotic signaling mediated by death ligands is a major 
obstacle for their therapeutic use. We therefore asked whether SC68896 sensitized human 
glioma cells to TRAIL- and CD95L-induced cell death. LNT-229 and LN-308 cells were 
treated with SC68896 at different concentrations and stimulated with TRAIL or CD95L for 20 
h. Both glioma cell lines were strongly sensitized by SC68896 to TRAIL- and CD95L-
induced cell death at conditions where either agent alone had little or no effect (Fig. 4A and 
B, upper panels). Selected survival data were analyzed by the fractional product method 
revealing a considerable synergistic activity of SC68896 with both death receptor ligands 
(Fig. 4A and B, lower panels). The synergistic action of SC68896 and death ligands was also 
confirmed by a statistical analysis based on the Chou-Talalay method (Suppl. Fig. 2). Light 
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microscopic analysis confirmed that the observed loss in cell density was due to decreased 
survival since the cells rounded off and detached (data not shown). 
We next assessed whether the cell surface expression of the TRAIL and CD95 receptors was 
induced by the inhibition of the proteasome through SC68896 as one possible explanation for 
this sensitization. To this end, we exposed LNT-229 and LN-308 human glioma cell lines to 
SC68896 and monitored the surface expression of DR4, DR5, DcR1, DcR2 and CD95 by 
flow cytometry. DR4 cell surface levels were moderately upregulated in LNT-229 but not in 
LN-308 cells (Fig. 4C). In contrast, the surface expression of DR5 was strongly induced in 
both cell lines (Fig. 4D). The surface expression of the decoy receptors DcR1 and DcR2 
remained unchanged. Similarly, CD95 levels on the cell surface were not induced by 
SC68896 (data not shown). 
 
Systemic and local application of SC68896 to glioma-bearing mice prolongs their 
survival  
The efficacy of SC68896 as a proteasome inhibitor that delays the growth of malignant 
glioma cells was subsequently assessed in vivo in an intracerebral glioma xenograft mouse 
model. Starting 8 days after stereotactic implantation of LNT-229 tumors, the mice were 
treated intraperitoneally on 5 days per week with 150 mg/kg SC68896 or vehicle as a control 
until they developed neurological symptoms and had to be sacrificed. The median survival 
was prolonged from 50.5 days in vehicle-treated mice to 60 days for the SC68896 group (Fig. 
5A; p<0.01 by Mann-Whitney-Wilcoxon test). To allow for an examination of the in vivo 
efficacy of SC68896 to target the proteasome, blood samples were taken from 6 mice of each 
group after 15 days of therapy. The activity of the proteasome was significantly reduced in the 
samples of SC68896-treated animals (Fig. 5B). Since local application of anti-tumor 
compounds is also a feasible delivery method, we additionally checked whether an 
intratumoral administration of SC68896 also inhibited the growth of intracerebral glioma 
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xenografts. To this end, 80 µg of SC68896 or 2 µl of DMSO were injected intratumorally on 
days 7, 14 and 21 after tumor implantation. Animals that were treated with DMSO developed 
neurological symptoms and had to be sacrificed earlier than animals that received SC68896. 
Survival at 55 days was 0% with vehicle treatment, but 83% with SC68896 administration 
(p<0.01, Fig. 5C). Two mice per group were sacrificed after the second administration of 
DMSO or the proteasome inhibitor for histological analyses. Treatment with SC68896 led to 
smaller tumors with larger necrotic areas (Fig. 5D, upper panel). The proliferation of glioma 
cells, assessed by Ki-67 staining, was reduced in mice that had received the proteasome 
inhibitor. We also noticed modest differences in p21 staining and apoptotic cells, this is, 
positive in the TUNEL assay, with a preference to SC68896-treated tumors (Fig. 5D). No 
differences were detected on the level of angiogenesis, assessed by vWF staining (data not 
shown).  
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DISCUSSION 
 
The survival of patients affected by malignant gliomas is still poor. The major obstacle to 
overcome is the resistance of glioma cells to undergo therapeutically induced cell death. The 
proteasome represents a potential target for novel therapeutic approaches since cancer cells 
are believed to be more dependent on proteasomal activity because of the accumulation of 
more misfolded and mutated proteins (14). Proteasome inhibitors have already entered the 
clinic and proven their efficacy against haematological malignancies and solid tumors. Here 
we report the characterization of a novel small molecule, SC68896, which inhibits the 
proteasome of glioma cells with subsequent induction of cell cycle arrest and apoptosis. Of 
note, short-time exposure of SC68896 also led to significant effects on glioma cells which 
might have important ramifications for its clinical use (Fig. 1D). As described for other 
proteasome inhibitors, SC68896 arrested glioma cells in G2/M and induced the accumulation 
of p21 and p27 in a p53-independent manner (Fig. 2B) (15). RNA interference-mediated 
silencing of wild-type p53 in LNT-229 glioma cells also did not affect the inhibition of 
proteasomal activity by SC68896. This is not unexpected since p53-dependent effects act 
downstream of the proteasome. Specific silencing of p53 also allowed clarifying its role for 
the susceptibility of LNT-229 glioma cells to proteasome inhibition. Interestingly, p53-
depleted cells were less vulnerable to the deleterious effects of proteasome inhibition (Fig 
2D).  
Exposure of glioma cells to SC68896 was accompanied by the induction of cell death and the 
cleavage of caspases and PARP (Fig. 3). Other compounds that target the proteasome act in a 
similar way on glioma and other neoplastic cell lines (16, 17). At equimolar concentrations, 
SC68896 is less potent than the proteasome inhibitor bortezomib (Suppl. Fig. 1). However, 
the clinical perspectives for proteasome inhibitors are determined by the doses that are 
tolerated in vivo. In that regard, it is noteworthy that SC68896 is the first proteasome inhibitor 
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that exerts anti-glioma activity in an experimental glioma model in vivo (Fig. 5). Since these 
compounds may not only influence glioma cell survival directly but also through indirect 
implications on their susceptibility toward apoptotic stimuli (18), we were further interested in 
the potential of SC68896 to sensitize glioma cells to death ligands. Although the proapoptotic 
TRAIL receptors DR4 and DR5 are expressed on human glioma cell lines (19), only a 
minority of glioma cells is sensitive to TRAIL. Smac agonists which antagonize the anti-
apoptotic effector protein X-linked inhibitor of apoptosis protein (XIAP) are one option to 
overcome TRAIL resistance in glioma cells in vivo (20). Bortezomib has also been described 
to sensitize glioma cell to different apoptotic stimuli (21, 22). We employed LNT-229 and 
LN-308 glioma cells for this study which are resistant to TRAIL when applied alone. 
SC68896 efficiently sensitized resistant glioma cells to TRAIL and CD95L (Fig. 4 A and B). 
We observed a pronounced synergy between SC68896 and both death receptor ligands (Fig. 4 
and Suppl. Fig. 2). This effect was independent of p53 since LN-308 cells do not express p53. 
The TRAIL receptors DR4 and DR5 are damage-inducible genes with subsequent 
upregulation of their expression on the cell surface on neoplastic cells leading to a 
sensitization  for TRAIL-induced apoptosis (23, 24). We found that SC68896 induces the 
expression of DR4 and DR5 on the cell surface while the expression of DcR1 and DcR2 
remaines unaffected (Fig. 4C, D). The enhanced receptor levels at the cell surface were 
paralleled by a sensitization to TRAIL-induced apoptosis (Fig. 4). However, we cannot 
exclude other mechanisms that contribute to the SC68896-mediated sensitization to TRAIL. 
Accordingly, the fact that a sensitization to CD95L occurs without an upregulation of cell 
surface-bound CD95 may also easily be explained by the huge variety of anti-apoptotic 
mechanisms present in glioma cells and affected by proteasome inhibition. Based on these 
results, a combined administration of SC68896 with a death receptor ligand may be a 
promising clinical approach that warrants further exploration. 
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Most importantly, we also provide in vivo data demonstrating the efficacy of SC68896 against 
established experimental gliomas. In contrast, no such activity was demonstrated for 
bortezomib against U87MG and TCG3 glioma xenografts in nude mice and for ritonavir in 
the rat 9L glioma model (6, 25). Systemic or local administration of SC68896 led to increased 
survival of these mice (Fig. 5A,C). As assessed by immunohistochemistry, the proliferation 
rate of glioma cells was markedly decreased after intratumoral administration of SC68896. 
These findings are in line with reduced Ki-67 levels after exposure of myeloma cells to a 
proteasome inhibitor (26). The failure of SC68896 to establish long-lasting control of tumor 
growth may result from insufficient levels in blood and tumor after intraperitoneal 
administration (Fig. 5B). The lack of a complete eradication of the tumor by intratumoral 
injection of SC68896 may be explained by the limited number of only 3 applications and an 
uncertain depth of penetration. Although central parts of these tumors were necrotic (Fig. 5D), 
the inhibitor presumably did not reach cells at the tumor border leading to a lack of sustained 
tumor growth control. This is consistent with the relatively low number of apoptotic or p21-
positive cells. Continuous administration as used in clinical trials with convection-enhanced 
delivery may allow for a more pronounced anti-tumor activity. Summarized, this data set 
demonstrates the in vitro and in vivo activity of SC68896 against malignant glioma cells. The 
fact that SC68896 exerts anti-glioma effects in vivo and prolongs the survival of glioma-
bearing mice, delineates SC68896 as a novel promising compound that warrants evaluation in 
a clinical phase I trial for patients with malignant glioma. 
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Figure legends 
 
Fig. 1. SC68896 inhibits the proliferation of cancer cells. A. Tumor cell lines from different 
origin were treated with increasing concentrations of SC68896 for 24 h (diamonds), 48 h 
(filled squares) or 72 h (open squares). Cell viability was assessed by MTT assay for K562 
cells or cell density by crystal violet staining for all other cell lines. B, C. The growth of 4 
different glioma cell lines (B) and freshly isolated glioma cells (C) after exposure to SC68896 
was assessed by crystal violet staining. The proteasome inhibitor was administered for 24, 48 
or 72 h. D. LNT-229 glioma cells were exposed to SC68896 for 1 h (diamonds), 3 h (filled 
squares), 6 h (triangles) or continuously (open squares) and examined after 24 h (left panel). 
The same experiment with a read-out after 72 h is shown in the right panel. Statistically 
significant changes compared with untreated cells are marked with asterisks (* p<0.05; ** 
p<0.01, two-sided Student’s t-test). 
 
Fig. 2. SC68896 inhibits the proteasomal activity of glioma cells and induces cell cycle 
arrest in glioma cells. A. LNT-229 glioma cells were exposed to different concentrations of 
SC68896 for 3 h (open bars: 0.1 µM, striped bars: 1 µM, filled bars: 10 µM). Activities of 3 
enzymatic sites were separately determined at this point and at 3, 9 or 21 h after removal of 
the compound or continuous exposure for 24 h. Statistically significant changes compared 
with untreated cells are marked with asterisks (* p<0.05; ** p<0.01, two-sided Student’s t-
test). B. After exposure to SC68896 for 24 h, whole cell lysates of LNT-229 control (left) or 
p53si (right) glioma cells were assessed by immunoblot for the expression of p21 and p27 
using GAPDH as a reference. C. LNT-229 cells were treated with various concentrations of 
SC68896 for 24 h, fixed, permeabilized, stained with PI and analyzed by flow cytometry. The 
figure shows representative examples of flow cytometry profiles and the distribution of the 
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cells to the indicated histogram regions (M1: sub-G1, M2: G1, M3: S, M4: G2/M). D. The 
expression of p53 was assessed by immunoblot in LNT-229 control or p53si cells (inset). 
LNT-229 control (black squares) or p53si cells (open diamonds) were exposed to SC68896 
with the indicated concentrations for 24 h. Cell density was assessed by crystal violet staining 
(upper panel). The chymotryptic proteasomal activity of LNT-229 control or p53si cells was 
measured after treatment with SC68896 for 3 h (lower panel). Statistically significant 
differences between LNT-229 control and p53si cells are marked with asterisks (* p<0.05; ** 
p<0.01, two-sided Student’s t-test). 
 
Fig. 3. SC68896 induces apoptosis in glioma cells. A. LNT-229 glioma cells were exposed 
to SC68896 at different concentrations for 24 h and analyzed for AnxV-fluorescein 
isothiocyanate/PI staining by flow cytometry. Data are expressed as mean percentages of 
either AnxV-positive and PI-negative (apoptotic) or AnxV- and PI-positive (necrotic) cells 
(representative experiment, n = 3). The data are summarized in the lower panel with early 
apoptotic cells (triangles), necrotic cells (diamonds) and their sum as the net cytotoxicity 
(closed squares). Cell density after exposure of LNT-229 glioma cells to SC68896 for 24 h 
was assessed by cristal violet staining (open squares). B, C. LNT-229 cells were treated with 
SC68896 for 24 h. Immunoblot analysis for caspase 8, caspase 3 and cleaved caspase 3 (B) or 
PARP (C) was performed as described. GAPDH or -actin were used as references. 
 
Fig. 4. SC68896 sensitizes human glioma cell lines to TRAIL- and CD95L-induced cell 
death. A, B. The cells were treated with the indicated concentrations of SC68896 and TRAIL 
(A) or CD95L (B). Cell density was assessed by crystal violet staining after 20 h (upper 
panels). Selected data are displayed according to the fractional product method (lower 
panels). The expected combined effects of SC68896 and TRAIL in case of independent 
mechanisms of action are designated as “predicted”. A synergy between both compounds was 
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assumed when the “observed” growth inhibition of the combined treatment (black bars) 
exceeded the “predicted” growth inhibition (dark grey bars) by > 30%. C, D. LNT-229 or LN-
308 cells were treated with different concentrations of SC68896 for 20 h. Cell surface 
expression of DR4 (C) and DR5 (D) was analyzed by flow cytometry. SFI values for both 
receptors are displayed.  
 
Fig. 5. Local or systemic administration of SC68896 prolongs the survival of glioma-
bearing mice. A, B. LNT-229 cells were inoculated intracerebrally in athymic CD1 nude 
mice. The animals were treated intraperitoneally with SC68896 (150 mg/kg body weight; 
solid lines) or vehicle (dotted lines). The mice were observed in daily intervals and killed at 
the onset of neurological symptoms. Survival data for 14 animals per group are presented as a 
Kaplan-Meier plot (A). Blood samples were taken from 6 mice of each group after 15 days of 
treatment. The enzymatic activity of the proteasome was measured with the Proteasome-Glo 
kit (B). C. LNT-229 cells were implanted into the right striatum of nude mice. 80 µg of 
SC68896 (solid lines) or 2 µl DMSO (dotted lines) were injected intratumorally on days 7, 14 
and 21 after tumor implantation (arrows). Survival data for 6 animals per group are presented 
as a Kaplan-Meier plot. D. After 2 intratumoral applications of DMSO or SC68896 (day 15 
after tumor inoculation), the animals’ brains were removed, shock-frozen and stained as 
indicated. Tumor borders are marked with arrows in the upper panel (magnifications: HE x20, 
Ki-67 and p21 x100, TUNEL x200). 
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Supplementary Fig. 1. SC68896 and bortezomib inhibit the growth of malignant glioma 
cells. LNT-229 or U373MG glioma cells were treated with increasing concentrations of 
SC68896 (closed squares) or bortezomib (open squares) for the indicated periods of time. Cell 
density was assessed by crystal violet staining. Data are expressed as mean and standard 
deviation. Statistically significant changes compared with vehicle-treated cells are marked 
with asterisks (* p<0.05; ** p<0.01, two-sided Student’s t-test). 
 
Supplementary Fig. 2. Synergistic activity of SC68896 and death ligands on glioma cells. 
LNT-229 or LN-308 cells were treated with increasing concentrations of SC68896 and 
TRAIL or CD95L as indicated in Fig. 4. Cell density was assessed by crystal violet staining. 
Analysis of synergy was performed using the Calcusyn software. CI/fractional effect curves 
represent the CI versus the fraction of cells affected by SC68896 and TRAIL or CD95L in 
combination (x = CI value for a tested combination; CI: combination index, s.d.: standard 
deviation).  
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